Long-term survival after immunotherapy for uncontrolled locally advanced temporal bone squamous cell carcinoma followed by chemoradiotherapy: A case report.

Q4 Medicine
Precision Radiation Oncology Pub Date : 2024-06-28 eCollection Date: 2024-06-01 DOI:10.1002/pro6.1233
Jin Yan, Jiangdong Sui
{"title":"Long-term survival after immunotherapy for uncontrolled locally advanced temporal bone squamous cell carcinoma followed by chemoradiotherapy: A case report.","authors":"Jin Yan, Jiangdong Sui","doi":"10.1002/pro6.1233","DOIUrl":null,"url":null,"abstract":"<p><p>Temporal bone squamous cell carcinoma (TBSCC) is a rare and invasive malignant tumor. The common predisposing factors include a history of local radiotherapy and chronic suppurative otitis media. The current treatment approach for TBSCC primarily involves surgery, followed by adjuvant radiotherapy and chemotherapy, based on T staging and high-risk factors. Although patients with early-stage TBSCC have a high survival rate after treatment, the majority of patients are diagnosed in the intermediate to advanced stages, with extensive tumor involvement, posing challenges for surgical intervention. Definitive chemoradiotherapy (CRT) serves as a viable alternative for unresectable tumors. Constraints in administering curative radiation doses, due to the tolerance of surrounding organs, can lead to uncontrolled tumor growth. Although programmed cell death 1 inhibitors have demonstrated efficacy in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma, their application in TBSCC remains underexplored. Herein, we report a case of a 47-year-old man diagnosed with unresectable advanced and localized TBSCC. Following inadequate tumor control with primary chemoradiotherapy, immunotherapy was initiated, resulting in disease remission within a follow-up period of > 4 years.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"8 2","pages":"99-105"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935013/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pro6.1233","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Temporal bone squamous cell carcinoma (TBSCC) is a rare and invasive malignant tumor. The common predisposing factors include a history of local radiotherapy and chronic suppurative otitis media. The current treatment approach for TBSCC primarily involves surgery, followed by adjuvant radiotherapy and chemotherapy, based on T staging and high-risk factors. Although patients with early-stage TBSCC have a high survival rate after treatment, the majority of patients are diagnosed in the intermediate to advanced stages, with extensive tumor involvement, posing challenges for surgical intervention. Definitive chemoradiotherapy (CRT) serves as a viable alternative for unresectable tumors. Constraints in administering curative radiation doses, due to the tolerance of surrounding organs, can lead to uncontrolled tumor growth. Although programmed cell death 1 inhibitors have demonstrated efficacy in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma, their application in TBSCC remains underexplored. Herein, we report a case of a 47-year-old man diagnosed with unresectable advanced and localized TBSCC. Following inadequate tumor control with primary chemoradiotherapy, immunotherapy was initiated, resulting in disease remission within a follow-up period of > 4 years.

不受控制的局部晚期颞骨鳞状细胞癌经放化疗后免疫治疗后的长期生存:1例报告。
摘要颞骨鳞状细胞癌是一种罕见的侵袭性恶性肿瘤。常见的诱发因素包括局部放疗史和慢性化脓性中耳炎。目前TBSCC的治疗方法主要是手术,然后根据T分期和高危因素进行辅助放疗和化疗。虽然早期TBSCC患者治疗后生存率较高,但大多数患者诊断为中晚期,肿瘤受累广泛,给手术干预带来了挑战。明确的放化疗(CRT)是不可切除肿瘤的可行选择。由于周围器官的耐受性,治疗性放射剂量的限制可导致肿瘤生长不受控制。尽管程序性细胞死亡1抑制剂已经证明对头颈部鳞状细胞癌和皮肤鳞状细胞癌有效,但它们在TBSCC中的应用仍未得到充分探索。在此,我们报告一例47岁男性被诊断为晚期和局部TBSCC不可切除。在最初的放化疗对肿瘤控制不足后,开始了免疫治疗,在40年的随访期内疾病缓解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Precision Radiation Oncology
Precision Radiation Oncology Medicine-Oncology
CiteScore
1.20
自引率
0.00%
发文量
32
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信